These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18358108)

  • 1. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P; Girolomoni G
    Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.
    Bessis D; Charron A; Rouzier-Panis R; Blatière V; Guilhou JJ; Reynes J
    Eur J Dermatol; 2002; 12(1):99-102. PubMed ID: 11809610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.
    Dalmau J; Pimentel CL; Puig L; Peramiquel L; Roé E; Alomar A
    J Am Acad Dermatol; 2005 Jul; 53(1):62-6. PubMed ID: 15965422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin necrosis after injection of PEG-interferon alpha2b in an HCV-infected patient.
    Sparsa A; Loustaud-Ratti V; Alain S; Liozon E; Bédane C; Vidal E
    Acta Derm Venereol; 2004; 84(5):415-6. PubMed ID: 15503367
    [No Abstract]   [Full Text] [Related]  

  • 7. Local blistering reaction complicating subcutaneous injection of pegylated interferon in a patient with hepatitis C.
    Gallina K; Brodell RT; Naffah F; Nedorost S
    J Drugs Dermatol; 2003 Jan; 2(1):63-7. PubMed ID: 12852384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject.
    Montesu MA; Siddi V; Satta R; Pirodda C; Cottoni F
    Acta Derm Venereol; 2007; 87(5):433-4. PubMed ID: 17721655
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C.
    Jansen PL; De Bruijne J
    Expert Opin Investig Drugs; 2012 Jan; 21(1):111-8. PubMed ID: 22126968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Devices for the safe performance of self-injection of interferon therapy for chronic hepatitis C].
    Kurihara T; Mikata R; Yokosuka O
    Nihon Rinsho; 2006 Jul; 64(7):1368-73. PubMed ID: 16838658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 12. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC; Lu SN; Lin MC
    Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
    [TBL] [Abstract][Full Text] [Related]  

  • 13.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z; Ji F; Zheng Y; An J; Peng Z
    Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
    [No Abstract]   [Full Text] [Related]  

  • 14. Allergic sensitization to pegylated interferon-α results in drug eruptions.
    Meller S; Gerber PA; Kislat A; Hevezi P; Göbel T; Wiesner U; Kellermann S; Bünemann E; Zlotnik A; Häussinger D; Erhardt A; Homey B
    Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].
    Waltschew A
    Pathologe; 2016 Mar; 37(2):184-6. PubMed ID: 26769217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fatal Outcome for subcutaneous administration of Pegylated IFN alpha 2b in a man with Chronic C hepatitis under treatment with traditional bitherapy].
    Domínguez Gozalo A; Hidalgo Correas FJ; García Benayas E; García Díaz B
    Farm Hosp; 2015 May; 39(3):186-8. PubMed ID: 26005896
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegylated interferon monotherapy for chronic hepatitis C.
    Heathcote J; Zeuzem S
    Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.